Triple Negative Breast Neoplasms
60
14
20
16
Key Insights
Highlights
Success Rate
55% trial completion
Published Results
15 trials with published results (25%)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 65/100
21.7%
13 terminated out of 60 trials
55.2%
-31.3% vs benchmark
13%
8 trials in Phase 3/4
94%
15 of 16 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 16 completed trials
Clinical Trials (60)
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
A Study of Pembrolizumab and Cryoablation in People With Breast Cancer
Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss
A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Bicalutamide and Abemaciclib in Inoperable or Metastatic Androgen Receptor-positive Triple-negative Breast Cancer
Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009)
A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer
Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC
Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody Avelumab
Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer